Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab

被引：0
|
作者：
Gudesblatt, Mark [1 ,2 ]
Zarif, Myassar [2 ]
Bumstead, Barbara [2 ]
Buhse, Marijean [2 ]
Kaczmarek, Olivia [2 ]
Li, Hanyue [3 ]
Sun, Zhaonan [3 ]
Scott, Nicole [3 ]
Mendoza, Jason P. [3 ]
Avila, Robin L. [3 ]
机构：
[1] Langone South Shore Neurol Associates, 77 Medford Ave, Patchogue, NY 11772 USA
[2] NYU Langone South Shore Neurol Associates PC, Patchogue, NY USA
[3] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL | 2023年 / 9卷 / 04期
关键词：
Multiple sclerosis; natalizumab; COVID-19; vaccine;
D O I：
10.1177/20552173231218117
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The immunomodulatory effects of disease-modifying therapies for multiple sclerosis might affect the immune response to vaccines for severe acute respiratory syndrome coronavirus 2. We analyzed the severe acute respiratory syndrome coronavirus 2-specific antibody response and lymphocyte profile before and after Ad26.COV2.S (Johnson & Johnson) vaccination in natalizumab-treated patients with multiple sclerosis. There was a 72-fold increase in mean anti-severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G levels 4 weeks after vaccination and a 137-fold increase after 6 months. Other immune signals were within normal ranges. Natalizumab-treated patients with multiple sclerosis had a robust immune response to Ad26.COV2.S vaccine, and other immune signals were not significantly affected.
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination
    Yocum, Andrew
    Simon, Erin L.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2021, 49 : 441.e3 - 441.e4
  • [22] Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets
    Grothe, Christoph
    Steffen, Falk
    Bittner, Stefan
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2021, 13
  • [23] Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study
    Krajnc, Nik
    Hegen, Harald
    Traxler, Gerhard
    Leutmezer, Fritz
    Di Pauli, Franziska
    Kornek, Barbara
    Rommer, Paulus
    Zulehner, Gudrun
    Riedl, Katharina
    Duerauer, Sophie
    Bauer, Angelika
    Kratzwald, Sarah
    Klotz, Sigrid
    Winklehner, Michael
    Deisenhammer, Florian
    Guger, Michael
    Hoeftberger, Romana
    Berger, Thomas
    Bsteh, Gabriel
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 65
  • [24] Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
    Hamzavi, Seyedeh Sadigheh
    Bahrololoom, Rosemina
    Saeb, Sepideh
    Marandi, Nahid Heydari
    Hosseini, Marzieh
    Abadi, Alimohammad Keshtvarz Hesam
    Jamalidoust, Marzieh
    BMC IMMUNOLOGY, 2024, 25 (01)
  • [25] Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
    Altieri, Manuela
    Capuano, Rocco
    Conte, Miriana
    Donnarumma, Giovanna
    Grimaldi, Elena
    Coppola, Nicola
    Galdiero, Massimiliano
    D'Ambrosio, Alessandro
    Tedeschi, Gioacchino
    Gallo, Antonio
    NEUROLOGICAL SCIENCES, 2022, 43 (05) : 2947 - 2949
  • [26] Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
    Manuela Altieri
    Rocco Capuano
    Miriana Conte
    Giovanna Donnarumma
    Elena Grimaldi
    Nicola Coppola
    Massimiliano Galdiero
    Alessandro d’Ambrosio
    Gioacchino Tedeschi
    Antonio Gallo
    Neurological Sciences, 2022, 43 : 2947 - 2949
  • [27] Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
    van Kempen, Z. L. E.
    Wieske, L.
    Stalman, E. W.
    Kummer, L. Y. L.
    van Dam, P. J.
    Volkers, A. G.
    Boekel, L.
    Toorop, A. A.
    Strijbis, E. M. M.
    Tas, S. W.
    Wolbink, G. J.
    Lowenberg, M.
    van Sandt, C.
    ten Brinke, A.
    Verstegen, N. J. M.
    Steenhuis, M.
    Kuijpers, T. W.
    van Ham, S. M.
    Rispens, T.
    Eftimov, F.
    Killestein, J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [28] Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
    Achtnichts, Lutz
    Jakopp, Barbara
    Oberle, Michael
    Nedeltchev, Krassen
    Fux, Christoph Andreas
    Sellner, Johann
    Findling, Oliver
    VACCINES, 2021, 9 (12)
  • [29] Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial
    Tica, Jelena
    Rezelj, Veronica V.
    Baron, Benoit
    van Paassen, Vitalija
    Zaidman, Javier
    Fairlie, Lee
    Scheper, Gert
    Le Gars, Mathieu
    Struyf, Frank
    Douoguih, Macaya
    Ruiz-Guinazu, Javier
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [30] Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
    Sadoff, J.
    Gray, G.
    Vandebosch, A.
    Cardenas, V
    Shukarev, G.
    Grinsztejn, B.
    Goepfert, P. A.
    Truyers, C.
    Van Dromme, I
    Spiessens, B.
    Vingerhoets, J.
    Custers, J.
    Scheper, G.
    Robb, M. L.
    Treanor, J.
    Ryser, M. F.
    Barouch, D. H.
    Swan, E.
    Marovic, M. A.
    Neuzil, K. M.
    Corey, L.
    Stoddar, J.
    Hard, K.
    Ruiz-Guinazu, J.
    Le Gars, M.
    Schuitemaker, H.
    Van Hoof, J.
    Stru, F.
    Douoguih, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (09) : 847 - 860
12345